Neovacs Begins a Phase I/II Clinical Trial for the Treatment of Crohn’s Disease
News Nov 04, 2008
Neovacs has announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNFa-kinoid, a therapeutic vaccine for the treatment of TNFa dependent auto-immune diseases such as rheumatoid arthritis, Crohn’s disease and psoriasis.
This study, to be conducted on patients suffering from Crohn’s disease, will relate to the identification of the optimal immunogenic dosage for neutralizing TNFa.
Postpartum hemorrhaging is the world's leading cause of death for women during and after childbirth, and the third-leading cause in the United States alone. The drug 'misoprostol' although affordable, has dangerous side effects, including uterine cramping, heart attack, toxicity in the brain and spinal cord, fetal death and fetal heart abnormalities. Development of a safer drug may be on the horizon, based on new researchREAD MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019